ZTI-SB 50 Capsule contains Itraconazole 50 mg, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the treatment of various fungal infections, including dermatophytosis, onychomycosis, blastomycosis, histoplasmosis, and aspergillosis. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the synthesis of ergosterol, a key component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. ZTI-SB 50 Capsule is administered orally and demonstrates good bioavailability, with absorption enhanced by acidic gastric pH. It is recommended to be taken with food to optimize absorption. The drug is metabolized primarily by the liver via the CYP3A4 pathway and has a half-life of approximately 24-42 hours. Caution is advised in patients with hepatic impairment or congestive heart failure. Common adverse effects include gastrointestinal disturbances, headache, and rash. Due to potential drug interactions, concurrent use with medications metabolized by CYP3A4 should be carefully monitored. ZTI-SB 50 Capsule should be used under medical supervision, with dosage and duration tailored to the specific fungal infection and patient response.